ESMO 2019: Abstracts

The abstract submission system will open soon!

Abstract submission deadlines

Deadline Date and time
  • Abstracts
  • Trial in Progress
  • Intent to submit LBA
8 May 2019, 21:00 CEST*
Late-breaking abstracts 21 August 2019, 21:00 CEST*

*CEST = Central European Summer Time

Abstract submission categories

  • Basic science
  • Biomarkers
  • Breast cancer, early stage
  • Breast cancer, locally advanced
  • Breast cancer, metastatic
  • CNS tumours
  • Developmental therapeutics
  • Endocrine tumours
  • Gastrointestinal tumours, colorectal
  • Gastrointestinal tumours, non-colorectal
  • Genitourinary tumours, prostate
  • Genitourinary tumours, non-prostate
  • Gynaecological cancers
  • Haematological malignancies
  • Head and neck cancer, excluding thyroid
  • Immunotherapy of cancer
  • Melanoma and other skin tumours
  • Neuroendocrine tumours
  • New diagnostic tools
  • NSCLC, early stage
  • NSCLC, locally advanced
  • NSCLC, metastatic
  • Palliative care
  • Psycho-oncology
  • Public policy
  • Sarcoma
  • SCLC
  • Supportive care
  • Thoracic malignancies, other
  • Thyroid cancer
  • Translational research
  • Tumour biology and pathology
  • Miscellaneous

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO 2019. 

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on 8 May 2019. 

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 21 August 2019, 21:00 CEST (Central European Summer Time).

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO 2019. 

It is expected that abstracts submitted as Trial in Progress (TiP) are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design 

Please note:

  • Recruitment must have already begun or have been completed by the abstract submission deadline of 8 May 2019.
  • Abstracts including results or preliminary data will be rejected.
  • Encore TiP abstracts will NOT be accepted.

Trial in Progress abstracts will NOT be considered for Proffered Paper (oral) presentation or Poster Discussion

Presentation and publication of accepted abstracts

The ESMO 2019 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

  • Presidential Symposium: Oral presentations by authors of the very best submitted abstracts containing cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
  • Proffered Paper: Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Poster Discussion: Presentation and analysis by an invited speaker highlighting important findings within a disease type or about a common theme plus interactive audience discussion.
  • Poster: Display sessions for review, discussion and questions. Rotated by category, posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work. 

All accepted abstracts, including Late-breaking, will be published online only in the ESMO 2019 Abstract Book.

Merit Awards

A restricted number of Merit Awards are reserved for candidates under 40 years of age. Selection of Merit Awards is based on the quality of accepted abstracts as reviewed by the ESMO 2019 Scientific Committee.

More information can be found in the Abstract regulations.